NCT06666803 Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
| NCT ID | NCT06666803 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IHU Strasbourg |
| Condition | PDAC - Pancreatic Ductal Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-01-27 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts. Only 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'. The aim of the study presented here is to validate these organoids on the basis of the following characteristics: (i) morphological and proliferative characteristics, (ii) recapitulation of the genetic characteristics of the original tumour, (iii) expression of tumour markers.
Eligibility Criteria
Inclusion Criteria: * Adult patient over 18 years of age. * Patient undergoing echo-endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Suspicion of pancreatic lesion * Patient able to receive and understand information relating to the research protocol and to give consent. * Patient affiliated to the French social security system. Exclusion Criteria: * Patient not programmed for endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB. * Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN) * Patient with acute pancreatitis within 4 weeks prior to EUS * Pregnant or breast-feeding patient * Patient under court protection. * Patient under guardianship or curatorship. * Patient in a situation of social vulnerability. * Patient under legal protection or unable to express his/her opposition.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06666803 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PDAC - Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06666803 currently recruiting?
Yes, NCT06666803 is actively recruiting participants. Contact the research team at armelle.takeda@ihu-strasbourg.eu for enrollment information.
Where is the NCT06666803 trial being conducted?
This trial is being conducted at Strasbourg, France, Strasbourg, France.
Who is sponsoring the NCT06666803 clinical trial?
NCT06666803 is sponsored by IHU Strasbourg. The trial plans to enroll 60 participants.